BMRN

BMRN

USD

BioMarin Pharmaceutical Inc. Common Stock

$52.520-0.040 (-0.076%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$52.560

High

$52.760

Low

$51.800

Volume

2.96M

Company Fundamentals

Market Cap

10.1B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.34M

Exchange

NMS

Currency

USD

52-Week Range

Low $51Current $52.520High $73.51

Related News

Analyst Upgrades

Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical with a Outperform and lowers the price target from $95 to $88.

View more
Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88
Analyst Upgrades

Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80

Truist Securities analyst Joon Lee maintains BioMarin Pharmaceutical with a Buy and lowers the price target from $90 to $80.

View more
Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $90 to $70.

View more
Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70
Analyst Upgrades

Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80

Barclays analyst Gena Wang maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $86 to $80.

View more
Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical with a Neutral and lowers the price target from $60 to $55.

View more
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55
Analyst Upgrades

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $104 to $98.

PR Newswire

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with...